Analysts Set Pyxis Oncology, Inc. (NASDAQ:PYXS) PT at $8.80

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been assigned an average recommendation of “Buy” from the seven research firms that are currently covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued a report on the stock in the last year is $8.80.

Several research analysts have recently weighed in on PYXS shares. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Thursday, May 16th. Royal Bank of Canada restated an “outperform” rating and issued a $7.00 target price on shares of Pyxis Oncology in a research note on Friday, March 22nd. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $10.00 price target on shares of Pyxis Oncology in a research report on Tuesday, May 7th.

Institutional Investors Weigh In On Pyxis Oncology

Large investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC bought a new position in shares of Pyxis Oncology during the 3rd quarter valued at about $26,000. Schulhoff & Co. Inc. bought a new position in Pyxis Oncology during the third quarter valued at approximately $44,000. SG Americas Securities LLC purchased a new position in shares of Pyxis Oncology during the first quarter worth approximately $59,000. Cetera Advisors LLC bought a new stake in shares of Pyxis Oncology in the 1st quarter worth approximately $100,000. Finally, Radcliffe Capital Management L.P. purchased a new stake in shares of Pyxis Oncology in the 3rd quarter valued at $106,000. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Stock Down 0.3 %

PYXS stock opened at $3.37 on Friday. The stock has a 50-day simple moving average of $4.07 and a two-hundred day simple moving average of $3.92. Pyxis Oncology has a twelve month low of $1.35 and a twelve month high of $6.85. The firm has a market capitalization of $198.46 million, a PE ratio of -2.48 and a beta of 1.33.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings data on Saturday, May 11th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.19. The firm had revenue of $16.15 million for the quarter, compared to analysts’ expectations of $4.25 million. On average, equities research analysts anticipate that Pyxis Oncology will post -1.09 EPS for the current fiscal year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.